These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37901324)

  • 21. A novel variant translocation (1;9)(p22;q34) resulting in a DEK/NUP214 fusion gene in a patient with acute myeloid leukemia: A case report.
    Hao Q; Zhang Q; Li C; Wei S; Li Q; Song Y; Mi Y
    Oncol Lett; 2017 Dec; 14(6):7021-7024. PubMed ID: 29344131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia.
    Wang Q; Qiu H; Jiang H; Wu L; Dong S; Pan J; Wang W; Ping N; Xia J; Sun A; Wu D; Xue Y; Drexler HG; Macleod RA; Chen S
    Haematologica; 2011 Dec; 96(12):1808-14. PubMed ID: 21880637
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Zhou MH; Yang QM
    Oncol Lett; 2014 Sep; 8(3):959-962. PubMed ID: 25120641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression of SET-NUP214 fusion gene in patients with T-cell acute lymphoblastic leukemia and its clinical significance].
    Dai HP; Wang Q; Wu LL; Ping NN; Wu CX; Xie JD; Pan JL; Xue YQ; Wu DP; Chen SN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1047-51. PubMed ID: 23114116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Bertz H; Illerhaus G; Veelken H; Finke J
    Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse.
    Lim ABM; Curley C; Fong CY; Bilmon I; Beligaswatte A; Purtill D; Getta B; Johnston AM; Armytage T; Collins M; Mason K; Fielding K; Greenwood M; Gibson J; Hertzberg M; Wright M; Lewis I; Moore J; Curtis D; Szer J; Kennedy G; Ritchie D
    Intern Med J; 2018 Mar; 48(3):276-285. PubMed ID: 28628276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).
    Pigneux A; Labopin M; Maertens J; Cordonnier C; Volin L; Socié G; Blaise D; Craddock C; Milpied N; Bacher U; Malard F; Esteve J; Nagler A; Mohty M;
    Leukemia; 2015 Dec; 29(12):2375-81. PubMed ID: 26082270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Choi YJ; Min YK; Lee ST; Choi JR; Shin S
    Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.
    Cornelissen JJ; Breems D; van Putten WL; Gratwohl AA; Passweg JR; Pabst T; Maertens J; Beverloo HB; van Marwijk Kooy M; Wijermans PW; Biemond BJ; Vellenga E; Verdonck LF; Ossenkoppele GJ; Löwenberg B
    J Clin Oncol; 2012 Jun; 30(17):2140-6. PubMed ID: 22564995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.
    Tsirigotis P; Gkirkas K; Kitsiou V; Chondropoulos S; Athanassiades T; Thomopoulos T; Tsirogianni A; Stamouli M; Karagiannidi A; Siafakas N; Pappa V; Nagler A
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell acute lymphoblastic leukemia associated with complex karyotype and SET-NUP214 rearrangement: a case study and review of the literature.
    Lee SG; Park TS; Cho SY; Lim G; Park GJ; Oh SH; Cho EH; Chong SY; Huh JY
    Ann Clin Lab Sci; 2011; 41(3):267-72. PubMed ID: 22075511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic prediction of relapse in patients with acute leukemias after allogeneic transplantation: Joint model for minimal residual disease.
    Huang A; Chen Q; Fei Y; Wang Z; Ni X; Gao L; Chen L; Chen J; Zhang W; Yang J; Wang J; Hu X
    Int J Lab Hematol; 2021 Feb; 43(1):84-92. PubMed ID: 32881394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
    Díaz-Beyá M; Labopin M; Maertens J; Aljurf M; Passweg J; Dietrich B; Schouten H; Socié G; Schaap N; Schwerdtfeger R; Volin L; Michallet M; Polge E; Sierra J; Mohty M; Esteve J; Nagler A;
    Br J Haematol; 2020 Jun; 189(5):920-925. PubMed ID: 32020596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion.
    Shah N; Rakszawski K; Nickolich M; Ehmann C; Wirk B; Naik S; Rybka W; Zheng H; Mierski J; Silar B; Mackey G; Greiner R; Brown V; Claxton D; Mineishi S; Minagawa K
    Ann Hematol; 2021 Oct; 100(10):2585-2592. PubMed ID: 34322774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL.
    Ben Abdelali R; Roggy A; Leguay T; Cieslak A; Renneville A; Touzart A; Banos A; Randriamalala E; Caillot D; Lioure B; Devidas A; Mossafa H; Preudhomme C; Ifrah N; Dombret H; Macintyre E; Asnafi V
    Blood; 2014 Mar; 123(12):1860-3. PubMed ID: 24449214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.
    Luskin MR; Carroll M; Lieberman D; Morrissette JJD; Zhao J; Crisalli L; Roth DB; Luger SM; Porter DL; Reshef R
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1961-1967. PubMed ID: 27478011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1.
    Versluis J; Labopin M; Ruggeri A; Socie G; Wu D; Volin L; Blaise D; Milpied N; Craddock C; Yakoub-Agha I; Maertens J; Ljungman P; Huynh A; Michallet M; Deconinck E; Chevallier P; Passweg J; Ciceri F; Mohty M; Cornelissen JJ; Nagler A
    Blood Adv; 2017 Feb; 1(7):477-485. PubMed ID: 29296964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.